{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:47:44Z","timestamp":1791751664138,"version":"4.3.4"},"reference-count":50,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Therapeutic Goods Administration"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>There is an increasing interest in combining psilocybin or methylenedioxymethamphetamine with psychological support in treating psychiatric disorders. Although there have been several recent systematic reviews, study and participant numbers have been limited, and the field is rapidly evolving with the publication of more studies. We therefore conducted a systematic review of PubMed, MEDLINE, PsycINFO, the Cochrane Central Register of Controlled Trials, Embase, and CINAHL for randomised controlled trials of methylenedioxymethamphetamine and psilocybin with either inactive or active controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Outcomes were psychiatric symptoms measured by standardised, validated and internationally recognised instruments at least 2\u2009weeks following drug administration, Quality was independently assessed using the Cochrane risk of bias assessment tool and Grading of Recommendations Assessment, Development and Evaluation framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were eight studies on methylenedioxymethamphetamine and six on psilocybin. Diagnoses included post-traumatic stress disorder, long-standing\/treatment-resistant depression, obsessive-compulsive disorder, social anxiety in adults with autism, and anxiety or depression in life-threatening disease. The most information and strongest association was for the change in methylenedioxymethamphetamine scores compared to active controls in post-traumatic stress disorder ( k\u2009=\u20094; standardised mean difference\u2009=\u2009\u22120.86; 95% confidence interval\u2009=\u2009[\u22121.23, \u22120.50]; p\u2009&lt;\u20090.0001). There were also small benefits for social anxiety in adults with autism. Psilocybin was superior to wait-list but not niacin (active control) in life-threatening disease anxiety or depression. It was equally as effective as escitalopram in long-standing depression for the primary study outcome and superior for most of the secondary outcomes in analyses uncorrected for multiple comparisons. Both agents were well tolerated in supervised trials. Trial quality varied with only small proportions of potential participants included in the randomised phase. Overall certainty of evidence was low or very low using the Grading of Recommendations Assessment, Development and Evaluation framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Methylenedioxymethamphetamine and psilocybin may show promise in highly selected populations when administered in closely supervised settings and with intensive support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00048674221083868","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T05:29:46Z","timestamp":1647062986000},"page":"362-378","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":34,"title":["A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-2924","authenticated-orcid":false,"given":"Steve","family":"Kisely","sequence":"first","affiliation":[{"name":"School of Medicine, The University of Queensland, Woolloongabba, QLD, Australia"},{"name":"Addiction and Mental Health Services, Metro South Health Service, Woolloongabba, QLD, Australia"},{"name":"Departments of Psychiatry, Community Health & Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Connor","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A","family":"Somogyi","sequence":"additional","affiliation":[{"name":"Discipline of Pharmacology, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Queensland, Woolloongabba, QLD, Australia"},{"name":"Addiction and Mental Health Services, Metro South Health Service, Woolloongabba, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"bibr1-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13249"},{"key":"bibr2-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2008.10400637"},{"key":"bibr3-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0540-6"},{"key":"bibr4-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01524-1"},{"key":"bibr5-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"bibr6-00048674221083868","first-page":"3757891","volume":"2021","author":"Chiruta V","year":"2021","journal-title":"Social Science Research Network"},{"key":"bibr7-00048674221083868","unstructured":"COMPASS (2021) COMPASS pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression. www.globenewswire.com\/news-release\/2021\/11\/09\/2330134\/0\/en\/COMPASS-Pathways-announces-positive-topline-results-from-groundbreaking-phase-IIb-trial-of-investigational-COMP360-psilocybin-therapy-for-treatment-resistant-depression.html (accessed 6 January 2022)."},{"key":"bibr8-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5010-9"},{"key":"bibr9-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"bibr10-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1511424"},{"key":"bibr11-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00155"},{"key":"bibr12-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1037\/a0015808"},{"key":"bibr13-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2020.1826931"},{"key":"bibr14-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112749"},{"key":"bibr15-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"bibr16-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"bibr17-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184"},{"key":"bibr18-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0569-3"},{"key":"bibr19-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036476"},{"key":"bibr20-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120965915"},{"key":"bibr21-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.11.010"},{"key":"bibr22-00048674221083868","volume-title":"An Evaluation of the Therapeutic Value, Benefits and Risks of Methylenedioxymethamphetamine (MDMA) and Psilocybin for the Treatment of Mental, Behavioural or Developmental Disorders: A Report to the Therapeutic Goods Administration","author":"Kisely S","year":"2021"},{"key":"bibr23-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(99)00148-7"},{"key":"bibr24-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0324-9"},{"key":"bibr25-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01530-3"},{"key":"bibr26-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3"},{"key":"bibr27-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30135-4"},{"key":"bibr28-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110378371"},{"key":"bibr29-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"bibr30-00048674221083868","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110"},{"key":"bibr31-00048674221083868","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.1997.007"},{"key":"bibr32-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1933434"},{"key":"bibr33-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.07.076"},{"key":"bibr34-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040875"},{"key":"bibr35-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.020"},{"key":"bibr36-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112464827"},{"key":"bibr37-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118806297"},{"key":"bibr38-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1177\/0004867421998785"},{"key":"bibr39-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.05.001"},{"key":"bibr40-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"bibr41-00048674221083868","volume-title":"Clinical Memorandum Therapeutic Use of Psychedelic Substances","author":"Royal Australian and New Zealand College of Psychiatrists","year":"2020"},{"key":"bibr42-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.06.104"},{"key":"bibr43-00048674221083868","author":"Sch\u00fcnemann H","year":"2013","journal-title":"GRADE handbook for grading quality of evidence and strength of recommendations"},{"key":"bibr44-00048674221083868","doi-asserted-by":"publisher","DOI":"10.4300\/JGME-D-12-00156.1"},{"key":"bibr45-00048674221083868","unstructured":"Therapeutic Goods Administration (2021) Notice of final decisions to amend (or not amend) the current poisons standard in relation to psilocybin and MDMA. Available at: www.tga.gov.au\/scheduling-decision-final\/notice-final-decisions-amend-or-not-amend-current-poisons-standard-relation-psilocybin-and-mdma (accessed December 2021)."},{"key":"bibr46-00048674221083868","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090331"},{"key":"bibr47-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1817639"},{"key":"bibr48-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1007\/BF00412109"},{"key":"bibr49-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75706-1"},{"key":"bibr50-00048674221083868","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2021.02.270"}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674221083868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00048674221083868","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674221083868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:56:22Z","timestamp":1777373782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00048674221083868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1177\/00048674221083868"],"URL":"https:\/\/doi.org\/10.1177\/00048674221083868","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]}}}